title: [Efficacy of an adjuvant norethisterone acetate therapy (NEA) of endometrial carcinoma treated with primary surgery or irradiation].
abstract: The efficiency of NEA (norethisteronacetate) as an adjuvant hormone therapy in 196 pat. suffering from endometrial cancer has been evaluated in a prospective randomized trial. Primarily 93 patients had been operated on and 103 ones irradiated. From these 45 patients following surgery and 51 ones following radiation therapy had been treated with NEA. Schedule of adjuvant NEA therapy was for a time 6 ms 50 mg/d followed by 6 ms pause and so on till 5 years post op. 5 years survival in the operation group was 91.7 per cent without and 81.6 per cent with NEA, in the irradiated group 43.1 per cent and 44.8 per cent respectively. Side effect (47.9%) were caused by NEA at least twice higher than in control groups.
  
  
  CONCLUSIONS
  the adjuvant hormone treatment without hormone receptor analysis is not recommendable.
authors.affiliation: Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Medizinischen Akademie, Erfurt.
authors.forename: W
authors.initials: W
authors.lastname: Krafft
authors.forename: R
authors.initials: R
authors.lastname: Steuckardt
authors.forename: E M
authors.initials: EM
authors.lastname: König
authors.forename: A
authors.initials: A
authors.lastname: Schirmer
authors.forename: G
authors.initials: G
authors.lastname: Schmeisser
authors.forename: D
authors.initials: D
authors.lastname: Brückmann
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
chemical_list: D000077563:Norethindrone Acetate; D009640:Norethindrone
vernacular_title: Die Effektivität einer adjuvanten norethisteronacetattherapie (NEA) nach primär operierten oder bestrahlten Endometriumkarzinomen.